The purpose of this study is to determine efficacy and toxicity of recombinant human epidermal growth factor (rhEGF) as a preventive drug of oral mucositis during intensive chemotherapy with stem cell transplantation in patients with hematologic malignancies.
Inclusion Criteria: * Patients with confirmed diagnosis of hematologic malignancies including acute \& chronic leukemia, lymphoma, plasma cell dyscrasia, myelodysplastic syndrome, aplastic anemia, etc. * Patients who are planned to receive high-dose chemotherapy with SCT * ECOG performance status 0-2 * Informed consent Exclusion Criteria: * Patients having previous history of hypersensitivity to this drug or similar drugs * Patients having oral ulcer or herpes or severe dental disease at the time of inclusion * Patients received chemotherapy, radiotherapy, or surgery within 3 weeks * Patients who had finished clinical trials which could affect the results of this trial within 4 weeks or are attending one at the time of inclusion * Patients having another diseases which have worse prognosis than patients' hematologic malignancy * Patients with major psychotic disorder or drug/alcohol abuser * Women who are pregnant or breastfeeding * Refusal at patients' will * Inappropriate patients according to the investigators' opinion